Streetbeat News

FWBI

First Wave BioPharma Inc

https://www.azurrx.com/

CEO

James Sapirstein

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Open

2.93

Mkt cap

Volume

56K

High

3.04

P/E Ratio

-0.06

52-wk high

60.00

Low

2.84

Div yield

N/A

52-wk low

2.33

The article lists the stocks that gained and lost the most during Thursday's mid-day trading session. Progressive Corporation (NYSE:PGR) shares fell by 11.8% due to below-consensus Q2 results. Other notable losers include Viasat, Inc. (NASDAQ:VSAT) and Cryoport, Inc. (NASDAQ:CYRX). On the gainers' side, Synaptogenix, Inc. (NASDAQ:SNPX) and Jiuzi Holdings, Inc. (NASDAQ:JZXN) saw significant increases.

Portfolio Pulse from Lisa Levin

July 13, 2023 | 4:49 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 100 points. Delta Air Lines reported better-than-expected Q2 results with a 19% YoY adjusted operating revenue growth to $14.61 billion, beating the consensus of $14.46 billion. Shares of Jiuzi Holdings, Synaptogenix, and 60 Degrees Pharmaceuticals rose significantly. However, Viasat, Cryoport, and First Wave BioPharma shares dropped due to various reasons.

Portfolio Pulse from Lisa Levin

July 13, 2023 | 4:21 pm

US stocks traded higher with the Dow Jones gaining over 100 points. Producer prices for final demand in the U.S. rose 0.1% month-over-month in June. Jiuzi Holdings, Synaptogenix, and 60 Degrees Pharmaceuticals saw significant stock increases, while Viasat, Cryoport, and First Wave BioPharma experienced notable drops.

Portfolio Pulse from Lisa Levin

July 13, 2023 | 2:30 pm

First Wave BioPharma Inc's shares are trading lower after the company received topline results from its Phase 2 SPAN trial for the treatment of exocrine pancreatic insufficiency in cystic fibrosis patients. The preliminary data indicates that the primary efficacy endpoint was likely not achieved. The company plans to pursue an End-of-Phase 2 meeting with the FDA in the fourth quarter of 2023.

Portfolio Pulse from Vandana Singh

July 13, 2023 | 1:36 pm

During Thursday's pre-market session, several healthcare stocks experienced significant movements. Synaptogenix, Quince Therapeutics, Applied DNA Sciences, Comera Life Sciences, Novan, and Coeptis Therapeutics saw their shares rise, while First Wave BioPharma, CryoPort, Healthcare Triangle, Cadrenal Therapeutics, Petros Pharma, and Freeline Therapeutics experienced a decrease in their stock prices.

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 1:12 pm

First Wave BioPharma announced that preliminary data from its Phase 2 SPAN trial suggest that the primary efficacy endpoint was likely not achieved, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 12:27 pm

First Wave Biopharma has received topline results from its Phase 2 SPAN trial of formulated Adrulipase for Exocrine Pancreatic Insufficiency in Cystic Fibrosis patients. The preliminary data suggests that it is unlikely the primary efficacy endpoint was achieved.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 11:04 am

Over the past three months, five analysts have given bullish ratings to First Wave BioPharma (NASDAQ:FWBI) with an average price target of $11.6, a decrease of 27.5% from the previous average price target of $16.00. No bearish or neutral ratings were reported.

Portfolio Pulse from Benzinga Insights

June 29, 2023 | 3:01 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on First Wave BioPharma (NASDAQ:FWBI) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:14 am

First Wave BioPharma has dosed the final patient in the Phase 2 SPAN trial of Adrulipase for Exocrine Pancreatic Insufficiency in patients with Cystic Fibrosis. The trial uses an enhanced enteric microgranule delivery formulation. Topline results are expected by mid-2023.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 11:05 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.